Frank Rimerman Advisors LLC Has $501,000 Holdings in Edwards Lifesciences Co. (NYSE:EW)

Frank Rimerman Advisors LLC increased its stake in Edwards Lifesciences Co. (NYSE:EW) by 25.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,766 shares of the medical research company’s stock after purchasing an additional 1,392 shares during the period. Frank Rimerman Advisors LLC’s holdings in Edwards Lifesciences were worth $501,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. GSA Capital Partners LLP bought a new stake in Edwards Lifesciences during the 3rd quarter worth about $481,000. Oppenheimer & Co. Inc. lifted its position in Edwards Lifesciences by 3.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 38,186 shares of the medical research company’s stock worth $2,520,000 after buying an additional 1,441 shares in the last quarter. Impax Asset Management Group plc lifted its position in Edwards Lifesciences by 66.2% during the 3rd quarter. Impax Asset Management Group plc now owns 12,964 shares of the medical research company’s stock worth $855,000 after buying an additional 5,164 shares in the last quarter. CIBC Asset Management Inc lifted its position in Edwards Lifesciences by 6.6% during the 3rd quarter. CIBC Asset Management Inc now owns 125,400 shares of the medical research company’s stock worth $8,275,000 after buying an additional 7,749 shares in the last quarter. Finally, Empowered Funds LLC lifted its position in Edwards Lifesciences by 10.7% during the 3rd quarter. Empowered Funds LLC now owns 24,032 shares of the medical research company’s stock worth $1,586,000 after buying an additional 2,324 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $69.37 on Monday. The company’s 50 day moving average price is $71.74 and its two-hundred day moving average price is $70.34. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The firm has a market cap of $40.78 billion, a PE ratio of 9.95, a PEG ratio of 4.82 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. The Goldman Sachs Group upped their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Wolfe Research cut shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Truist Financial reaffirmed a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Barclays upped their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $79.95.

Insiders Place Their Bets

In related news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,189,770.56. This represents a 16.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,303 shares of company stock worth $3,715,776 in the last quarter. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.